Current Medicinal Chemistry - Volume 30, Issue 19, 2023

Introduction: This review concerns three species of berries, namely the high- -latitude cloudberry (Rubus chamaemorus) and arctic bramble (Rubus arcticus), and the high-altitude yellow raspberry (Rubus ellipticus). These plants are mostly exploited on a local basis as food or traditional remedies but could have a wider usage as nutraceuticals due to their richness in ellagitannins (ETs) and other phenolic compounds. ETs are hexahydroxydiphenoyl esters of carbohydrates and the largest group of hydrolysable tannins. They are distinctly antioxidant and bioactive compounds, and therefore, are considered as majorly responsible for the biological properties of ET-rich berries. The health benefits of ETs are mainly due to the release of ellagic acid and to their metabolic transformation by the gut microbiota into urolithins, and include, among others, anti-inflammatory, antiviral, anti-bacterial, and anticancer actions. Methods: Based on the literature searches in the Web of Science, Scopus, and PubMed databases, ethnobotanical, pharmaceutical, medicinal, and nutritional knowledge concerning the three berry species was covered. This includes empirical use of traditional preparations and experimental studies with various extracts and fractions from fruits and other plant portions, covering in vitro, preclinical, and clinical research. Results: The data reveal a wide spectrum of potential uses in health care, providing in some cases an experimental confirmation of traditional uses. Conclusion: The examined berry species can act as nutraceutical foods, having positive effects on regular consumers but could also be exploited in more technological ways to produce food complements from ET-rich extracts.

Platinum agents, which include cisplatin, oxaliplatin and carboplatin, are chemotherapeutic drugs that represent the first-line treatment for different types of solid tumors, such as ovarian, head and neck, testicular, and bladder cancers. Their beneficial effect is limited by the onset of drug resistance and severe toxicities, involving mainly ototoxicity, neurotoxicity and nephrotoxicity. Recent studies highlight the supplementation of herbal products, vitamins and minerals with antioxidant properties to prevent and protect from side effects. In particular, the introduction of nutraceuticals associated with chemotherapy has improved the patients’ quality of life. However, if from one side, complementary and alternative medicine ameliorates chemotherapeutics-induced toxicities, from the other side, it is important to take into consideration the possible interference with drug metabolism. This review aims to consider the current literature focusing on clinical trials that report an association between nutraceutical supplementation and platinum- based chemotherapy to prevent toxicities, highlighting both beneficial and side effects.

Background: Inflammatory bowel diseases (IBD), mainly Ulcerative colitis (UC) and Crohn’s disease (CD), are recurrent idiopathic non-infectious chronic diseases widely diffused worldwide and characterized by moderate to severe mucosal damage. Objective: This study aims to review the literature of the last 10 years to photograph preclinical and clinical data on the use of nutraceuticals in the prevention and treatment, combined with the conventional drugs, of IBD. Method: PubMed, MEDLINE, Embase, Web of Science, and ClinicalTrials.gov were used to search for the most recent publications on in vitro, in vivo, and clinical evidence on IBD and nutraceuticals, which were then assessed based on the originality and scientific rigor of the studies. Results: In the last decade, the interest in new healthy or therapeutic complementary or alternative approaches to conventional drugs in IBD has grown inexorably, as well as the incidence of these pathologies and the knowledge of their etiopathogenesis. In this context, a growing development of new nutraceutical products with a consequent increase in pre-clinical studies has been observed. However, this panorama does not yet translate into adequate clinical studies that can effectively endorse what was observed in pre-clinical studies; many of them are mostly aimed at resolving diseases related to IBD rather than IBD itself. Conclusion: Despite the promising pre-clinical data about nutraceuticals and IBD, we are still very far from being able to postulate an adequate nutraceutical treatment of these pathologies and further studies are necessary to support this hypothesis.

Background: Autoimmune diseases are chronic disorders in which the immune system does not recognize and attacks one self’s healthy components. In this context, although natural remedies might represent a promising therapeutic strategy, evidence regarding Citrus flavonoids is still controversial. Objective: To summarize and critically discuss the clinical evidence on the effects of Citrus flavonoids on managing autoimmune diseases. Method: A systematic review of articles has been carried out independently by two authors using MEDLINE, Scopus and ISI Web of Science databases. Search terms comprised keywords related to Citrus flavonoids and autoimmune diseases. The last search was performed on the 16th of March, 2021. No language restrictions were applied. Systematic review and study selection were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Before starting the review, the authors defined the types of articles to be included. Three reviewers independently carried out the extraction of papers. Results: Ten clinical studies fulfilled the eligibility criteria and were included in the final review. Conclusion: The studies discussed in this review are heterogeneous. Indeed, some studies suggest using Citrus flavonoids in the frame of autoimmune disorders, whereas others discourage it. Hence, this systematic review highlights the need for further large-scale clinical studies to define the exact role of Citrus flavonoids in managing autoimmune diseases (PROSPERO number CRD42021234903).

P2Y receptors (P2YRs) are G protein-coupled receptors that are activated by extracellular nucleotides. The P2Y6 receptor (P2Y6R) is specifically activated by UDP, causing PKC activation and intracellular calcium ion release through the PLC pathway. Based on receptor tissue distribution and related pathways, several studies have reported that P2Y6R plays a physiological role in mediating inflammation, which suggests that P2Y6R could be a promising molecular target for the treatment of inflammatory diseases. In the past ten years, several P2Y6R antagonists have been discovered as new therapeutic strategies for inflammatory diseases. In this article, we systematically summarize the role of P2Y6R in inflammation and highlight the anti-inflammatory mechanism of a key P2Y6R antagonist, MRS2578. Insight into recent progress on the discovery of P2Y6R antagonists is also discussed.